WIXLIB

Vismodegib as Novel Treatmentof periocular Basal cellCarcinoma A Mini Reviewby Hendrian Dwikoloso SoebagjoSubmission date: 20-Apr-2020 12:39AM (UTC 0800)Submission ID: 1301596362File name: l Treatment of periocular Basal cell Carcinoma A Mini Review.pdf (457.17K)Word count: 7912Character count: 42464

Vismodegib as Novel Treatment of periocular Basal cellCarcinoma A Mini ReviewORIGINALITY REPORT24%SIMILARITY INDEX13%21%0%INTERNET SOURCESPUBLICATIONSSTUDENT PAPERSPRIMARY SOURCES1Jason Mathis, Timothy Doerr, Edward Lin,Sherrif F. Ibrahim. "Oral Hedgehog PathwayInhibition as a Means for Ocular Salvage inLocally Advanced Intraorbital Basal CellCarcinoma", Dermatologic Surgery, 20192%Publication2Maya Eiger-Moscovich, Ehud Reich, Gil Tauber,Ori Berliner, Ayelet Priel, Guy Ben Simon, AmirAbd Elkader, Iftach Yassur. "Efficacy ofVismodegib for the Treatment of Orbital andAdvanced Periocular Basal Cell Carcinoma",American Journal of Ophthalmology, 20192%Publication345insights.ovid.comInternet Sourcewww.sysrevpharm.orgInternet SourceLim, Lik Thai, Pankaj K. Agarwal, David Young,Elliott Yann Ah-kee, and Charles J. M. Diaper.1%1%1%

"The Effect of Socio-Economic Status onSeverity of Periocular Basal Cell Carcinoma atPresentation :", Ophthalmic Plastic andReconstructive Surgery, ernet SourceSarah E. Coupland, Santosh U. Kafle, JakubKhzouz. "Cancers of the Eye and Orbit—Pathology and Genetics", Elsevier BV, 20181%1%Publication8"Basal Cell Carcinoma", Springer Science andBusiness Media LLC, 20201%Publication9H. Oliphant, J. Laybourne, K. Chan, A. Haridaset al. "Vismodegib for periocular basal cellcarcinoma: an international multicentre caseseries", Eye, 20201%Publication101112www.nice.org.ukInternet Sourcewww.cancer-genetics.orgInternet Sourcewww.nature.comInternet SourceAleksandar Sekulic, Michael R. Migden, Nicole1%1%1%

13Basset-Seguin, Claus Garbe et al. "Long-termsafety and efficacy of vismodegib in patientswith advanced basal cell carcinoma: final updateof the pivotal ERIVANCE BCC study", BMCCancer, 2017 1%Publication14151617docobook.comInternet Sourcebmccancer.biomedcentral.comInternet Sourcewww.ncbi.nlm.nih.govInternet SourceBrigitte Dreno, Nicole Basset‐Seguin, Ivor Caro,Huibin Yue, Dirk Schadendorf. "Clinical BenefitAssessment of Vismodegib Therapy in PatientsWith Advanced Basal Cell Carcinoma", TheOncologist, 2014 1% 1% 1% 1%Publication181920ysmu.amInternet Sourceascopubs.orgInternet SourceKatherine A. Lyseng-Williamson, Gillian M.Keating. "Vismodegib", American Journal ofClinical Dermatology, 2012Publication 1% 1% 1%

21"Kanerva’s Occupational Dermatology",Springer Science and Business Media LLC,2020 1%Publication2223242526eyewiki.orgInternet Sourceworldwidescience.orgInternet Source"posters", Annals of Oncology, Internet SourceCalzavara Pinton, Piergiacomo, Lisa Licitra,Katia Peris, Armando Santoro, and PaoloAntonio Ascierto. "Vismodegib in the treatmentof basal cell carcinoma: indications for clinicalpractice", Future Oncology, 2015. 1% 1% 1% 1% 1%Publication2728linknovate.comInternet Source&NA;, . "15th World Conference on Lung Cancer:", Journal of Thoracic Oncology, 2013. 1% 1%Publication29www.medicines.org.ukInternet Source 1%

30Richard A. Graham, Bert L. Lum, GlennMorrison, Ilsung Chang et al. "A Single DoseMass Balance Study of the Hedgehog PathwayInhibitor Vismodegib (GDC-0449) in HumansUsing Accelerator Mass Spectrometry", DrugMetabolism and Disposition, 2011 1%Publication31RA Graham. "Single- and Multiple-DoseIntravenous and Oral Pharmacokinetics of theHedgehog Pathway Inhibitor Vismodegib inHealthy Female Subjects : Vismodegib IV andoral pharmacokinetics", British Journal ofClinical Pharmacology, 03/2012 1%Publication323334clinicaltrials.govInternet Sourcejournals.sagepub.comInternet SourceAnthony M. Giannetti, Harvey Wong, Gerrit J. P.Dijkgraaf, Erin C. Dueber et al. "Identification,Characterization, and Implications of SpeciesDependent Plasma Protein Binding for the OralHedgehog Pathway Inhibitor Vismodegib (GDC0449)", Journal of Medicinal Chemistry, 2011 1% 1% 1%Publication35Paul A. van der Eerden, M. Eric F. Prins, Peter 1%

J. F. M. Lohuis, Fons A. J. M. Balm, Hade D.Vuyk. "Eighteen years of experience in Mohsmicrographic surgery and conventional excisionfor nonmelanoma skin cancer treated by asingle facial plastic surgeon and pathologist",The Laryngoscope, 2010Publication36Dessinioti, Clio, Michaela Plaka, and AlexanderJ Stratigos. "Vismodegib for the treatment ofbasal cell carcinoma: results and implications ofthe ERIVANCE BCC trial", Future Oncology,2014. et Sourcehrcak.srce.hrInternet Sourcef1000research.comInternet SourceUffe Høgh Olesen, Gael Clergeaud, KristofferKjærgaard Hendel, Kelvin Yeung et al."Enhanced and sustained cutaneous delivery ofvismodegib by ablative fractional laser andmicroemulsion formulation", Journal ofInvestigative Dermatology, 2020Publication 1% 1% 1% 1%

41M Nikanjam, P R Cohen, S Kato, J K Sicklick, RKurzrock. "Advanced Basal Cell Cancer:Concise Review of Molecular Characteristicsand Novel Targeted and Immune Therapeutics",Annals of Oncology, 2018 1%Publication4243www.accessdata.fda.govInternet Source"HEDGEHOG SIGNALING AND HUMANDISEASE", Annual Review of Genomics andHuman Genetics, 09/2002 1% 1%Publication44"Small Molecules in Oncology", SpringerScience and Business Media LLC, 2018 1%Publication4546hal.archives-ouvertes.frInternet Source"INVITED ABSTRACTS", Journal of ThoracicOncology, 2013 1% 1%Publication47Sekulic, Aleksandar, Michael R. Migden, KarlLewis, John D. Hainsworth, James A. Solomon,Simon Yoo, Sarah T. Arron, Philip A.Friedlander, Ellen Marmur, Charles M. Rudin,Anne Lynn S. Chang, Luc Dirix, Jeannie Hou,Huibin Yue, and Axel Hauschild. "Pivotal 1%

ERIVANCE basal cell carcinoma (BCC) study:12-month update of efficacy and safety ofvismodegib in advanced BCC", Journal of theAmerican Academy of Dermatology, 2015.Publication484950www.mdpi.comInternet Sourcewww.frontiersin.orgInternet SourceCorreia de Sá, Tiago Ribeiro, Roberto Silva, andJosé Manuel Lopes. "Basal cell carcinoma ofthe skin (part 2): diagnosis, prognosis andmanagement", Future Oncology, 2015. 1% 1% 1%Publication5152intjcancermanag.comInternet SourceSun, Michelle T., Albert Wu, Shyamala C.Huilgol, and Dinesh Selva. "Accuracy of Biopsyin Subtyping Periocular Basal Cell Carcinoma :",Ophthalmic Plastic and Reconstructive Surgery,2015. 1% 1%Publication5354link.springer.comInternet SourceLu, T, B Wang, Y Gao, M Dresser, RA Graham,and JY Jin. "Semi-Mechanism-Based Population 1% 1%

Pharmacokinetic Modeling of the HedgehogPathway Inhibitor Vismodegib : VismodegibPopulation Pharmacokinetics", CPTPharmacometrics & Systems Pharmacology,2015.Publication55R. A. Graham, B. L. Lum, S. Cheeti, J. Y. Jin, K.Jorga, D. D. Von Hoff, C. M. Rudin, J. C. Reddy,J. A. Low, P. M. LoRusso. "Pharmacokinetics ofHedgehog Pathway Inhibitor Vismodegib (GDC0449) in Patients with Locally Advanced orMetastatic Solid Tumors: the Role of Alpha-1Acid Glycoprotein Binding", Clinical CancerResearch, 2011 1%Publication56R. Dummer, P.A. Ascierto, N. Basset‐Seguin, B.Dréno et al. "Sonidegib and vismodegib in thetreatment of patients with locally advanced basalcell carcinoma: a joint expert opinion", Journal ofthe European Academy of Dermatology andVenereology, 2020 1%Publication57Ghassan K. Abou-Alfa, Lionel D. Lewis, PatriciaLoRusso, Michael Maitland et al."Pharmacokinetics and safety of vismodegib inpatients with advanced solid malignancies andhepatic impairment", Cancer Chemotherapy andPharmacology, 2017 1%

Publication58Budha, N R, A Frymoyer, G S Smelick, J Y Jin,M R Yago, M J Dresser, S N Holden, L Z Benet,and J A Ware. "Drug Absorption InteractionsBetween Oral Targeted Anticancer Agents andPPIs: Is pH-Dependent Solubility the AchillesHeel of Targeted Therapy?", ClinicalPharmacology & Therapeutics, 2012. 1%Publication59"Hedgehog signaling activation in human cancerand its clinical implications", Springer Scienceand Business Media LLC, 2011 1%Publication60Mariam Totonchy, David Leffell. "Emergingconcepts and recent advances in basal cellcarcinoma", F1000Research, 2017PublicationExclude quotesOnExclude bibliographyOnExclude matchesOff 1%

Vismodegib as Novel Treatment of periocular Basal cellCarcinoma A Mini ReviewGRADEMARK REPORTFINAL GRADEGENERAL COMMENTS/100InstructorPAGE 1PAGE 2PAGE 3PAGE 4PAGE 5PAGE 6PAGE 7PAGE 8PAGE 9

single facial plastic surgeon and pathologist", The Laryngoscope, 2010 Publication Dessinioti, Clio, Michaela Plaka, and Alexander J Stratigos. "Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial", Future Oncology, 2014. Publication mgend.med.kyoto-u.ac.jp Internet Source hrcak.srce.hr .